HR
COLL icon

Howe & Rusling’s Collegium Pharmaceutical COLL Stock Holding History

Howe & Rusling’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-106
Closed -$2K – 468
2022
Q3 		$2K Buy
+106
New +$1.87K ﹤0.01% 846

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Howe & Rusling's COLL Position: Q4 2022 in Review

Howe & Rusling sold out of Collegium Pharmaceutical (COLL) in Q4 2022, closing a stake of 106 shares — an estimated $2K sold.

Howe & Rusling first reported a position in COLL in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 179 funds tracked by Wall St. Rank hold COLL as of Q4 2022.

  • Howe & Rusling reported no remaining Collegium Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 106 Collegium Pharmaceutical shares in Q4 2022, an estimated $2K.
  • Howe & Rusling first reported a position in Collegium Pharmaceutical in Q3 2022 and held it in 1 quarter.
  • Howe & Rusling's Collegium Pharmaceutical position peaked at $2K in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.